Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Ludovica Scucchi(University of Rome Tor Vergata), Livia Biancone(University of Rome Tor Vergata), Loredana Sarmati(University of Rome Tor Vergata), Renato Massoud(University of Rome Tor Vergata), Elisabetta Lolli, Elisabetta Calabrese(Sapienza University of Rome), Silvia Bernardini(University of Bologna), Massimo Andreoni(University of Rome Tor Vergata), Benedetto Neri(University of Rome Tor Vergata), Michelangela Mossa, Irene Marafini(University of Rome Tor Vergata), Giovanni Monteleone(University of Rome Tor Vergata), C. Petruzziello, G. Sena, Beatrice Musumeci(Sapienza University of Rome)
Cited by 8
Related Papers
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669
Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal Tract
|Gastroenterology|2011|634
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis
|Clinical Gastroenterology and Hepatology|2014|405